Analyse à 12 mois d’ILLUMINATE-A, une étude de phase 3 du lumasiran : réduction durable de l’oxalate et des taux d’évènements de calculs rénaux dans l’hyperoxalurie primitive de type 1
Jeffrey M. Saland(Université Claude Bernard Lyon 1), John C. Lieske(Mayo Clinic), David J. Sas(Mayo Clinic), Georges Deschênes(Hôpital Robert-Debré), Michael J. Koren(Jacksonville Center for Clinical Research), Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), John M. Gansner(Brigham and Women's Hospital), Wesley Hayes(Great Ormond Street Hospital), Daniel G. Fuster(University Hospital of Bern), Anne‐Laure Sellier‐Leclerc(Hôpital Femme Mère Enfant), Eva Šimková(Université Claude Bernard Lyon 1), Kenji Fujita(Alnylam Pharmaceuticals (United States)), Yaacov Frishberg(Shaare Zedek Medical Center), Sander F. Garrelfs(Emma Kinderziekenhuis), Martin Coenen(University Hospital Bonn), Daniella Magen(Université Claude Bernard Lyon 1), Taylor Ngo(Boehringer Ingelheim (Germany)), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Sally A. Hulton(Birmingham Children's Hospital), Tracy L. McGregor(Université Claude Bernard Lyon 1), Jaap W. Groothoff(University of Amsterdam), J. Scott Overcash(Precision Research Institute), Kristin Meliambro(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
|The Lancet|2019|785
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505